ESMO WCGIC 2023 | Assessing treatment options for hepatocellular carcinoma

Lorenza Rimassa, MD, Humanitas University and IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses different therapies for hepatocellular carcinoma (HCC). Immunotherapies including atezolizumab plus bevacizumab, or durvalumab plus tremelimumab have replaced tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib in the first-line setting. For patients with contraindications, such as prior liver transplants, those with severe autoimmune disorders or those without access to immunotherapy, TKIs remain the treatment of choice. Whilst TKIs are also used for patients who progress on immune checkpoint inhibitors, robust data is currently unavailable after first-line immunotherapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.